Report Detail
(Post-pandemic Era)-Global The Neuraminidase Inhibitor Market Segment Research Report 2021
- RnM4352511 |
- 01 November, 2021 |
- Global |
- 80 Pages |
- XYZResearch |
- Pharma & Healthcare
Summary
The global economy is expected to expand 5.6% in 2021，global recovery is strong but uneven as many emerging market and developing economies continue to struggle with the COVID-19 pandemic, the world is unlikely to ever reach global herd immunity. However, the recovery in many countries is being held back by a resurgence of COVID-19 cases and lagging vaccination progress, as well as the withdrawal of policy support in some instances.
The annual U.S. economic growth rate slipped to -3.5% in 2020, but grew at a yearly pace of more than 6% in the previous two quarters of 2021. The economy of continental Europe bounced back in the second quarter after having contracted in both the fourth quarter of 2020 and the first quarter of 2021, as the vaccinations accelerated, and governments eased restrictions. Among major economies, the annualized growth rate was 6.1% in Germany, 3.6% in France, 11.2% in Italy, and 11.7% in Spain. The especially rapid growth in Spain and Italy was attributed to a surge in consumer spending, likely the result of an easing of economic restrictions.
Regional Economic Prospects: Growth in the East Asia and Pacific is projected to accelerate by 7.7% in 2021, Central Asia is forecast to grow by 3.9% this year, economic activity in the Middle East and North Africa is forecast to advance by 2.4%, South Asia is projected to expand by 6.8%.
The global The Neuraminidase Inhibitor market size was USD XX billion in 2021. It is likely to progress at a CAGR of XX% during the forecast period of 2022-2027, according to XYZResearch analysis, The segment in The Neuraminidase Inhibitor market is estimated to reach a market value of USD XX billion by 2021 from an initial market value of USD XX billion in 2021. China market value in 2021 is about USD XX billion, and China The Neuraminidase Inhibitor production is XX (K Units). US market value in 2021 is about USD XX billion, and US The Neuraminidase Inhibitor production is XX (K Units). Europe market value in 2021 is about USD XX billion, and Europe The Neuraminidase Inhibitor production is XX (K Units).
Regional Segmentation (Value; Revenue, USD Million, 2017 - 2027) of The Neuraminidase Inhibitor Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in The Neuraminidase Inhibitor Market?
GlaxoSmithKline
BioCryst
Gilead Sciences
F. Hoffman-La Roche
Daiichi Sankyo
...
Major Type of The Neuraminidase Inhibitor Covered in XYZResearch report:
Zanamivir
Oseltamivir
Peramivir
Laninamivir
Application Segments Covered in XYZResearch Market
Hospital Pharmacies
Drug Stores
Retail Stores
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global The Neuraminidase Inhibitor Market Segment Research Report 2021
1. Research Scope
2. Market Overview
- 2.1 Product Introduction, Application, Picture
- 2.2 Global The Neuraminidase Inhibitor Market by Value
- 2.2.1 Global The Neuraminidase Inhibitor Revenue by Type
- 2.2.2 Global The Neuraminidase Inhibitor Market by Value (%)
- 2.3 Global The Neuraminidase Inhibitor Market by Production
- 2.3.1 Global The Neuraminidase Inhibitor Production by Type
- 2.3.2 Global The Neuraminidase Inhibitor Market by Production (%)
3. The Major Driver of The Neuraminidase Inhibitor Industry
- 3.1 Historical & Forecast Global The Neuraminidase Inhibitor Demand
- 3.2 Largest Application for The Neuraminidase Inhibitor (2017-2027)
- 3.3 The Major Downstream Company in China Market 2021
4. Global and Regional The Neuraminidase Inhibitor Market
- 4.1 Regional Market Size in Terms of Production & Demand (2021)
- 4.2 Regional Market Share in Terms of Revenue (2019-2027)
- 4.3 Concentration Ratio (CR5& CR10) of The Neuraminidase Inhibitor Market
- 4.4 Mergers & Acquisitions, Expansion Plans
5. US The Neuraminidase Inhibitor Production, Demand (2017-2027)
- 5.1 Current and Estimated Production Breakdown by Type
- 5.2 Current and Estimated Demand Breakdown by Type
- 5.3 Current and Estimated Demand Breakdown by Application
- 5.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
- 5.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
6. Europe The Neuraminidase Inhibitor Production, Demand (2017-2027)
- 6.1 Current and Estimated Production Breakdown by Type
- 6.2 Current and Estimated Demand Breakdown by Type
- 6.3 Current and Estimated Demand Breakdown by Application
- 6.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
- 6.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
7. China The Neuraminidase Inhibitor Production, Demand (2017-2027)
- 7.1 Current and Estimated Production Breakdown by Type
- 7.2 Current and Estimated Demand Breakdown by Type
- 7.3 Current and Estimated Demand Breakdown by Application
- 7.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
- 7.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
8. Japan The Neuraminidase Inhibitor Production, Demand (2017-2027)
- 8.1 Current and Estimated Production Breakdown by Type
- 8.2 Current and Estimated Demand Breakdown by Type
- 8.3 Current and Estimated Demand Breakdown by Application
- 8.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
- 8.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
9. India The Neuraminidase Inhibitor Production, Demand (2017-2027)
- 9.1 Current and Estimated Production Breakdown by Type
- 9.2 Current and Estimated Demand Breakdown by Type
- 9.3 Current and Estimated Demand Breakdown by Application
- 9.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
- 9.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
10. Korea The Neuraminidase Inhibitor Production, Demand (2017-2027)
- 10.1 Current and Estimated Production Breakdown by Type
- 10.2 Current and Estimated Demand Breakdown by Type
- 10.3 Current and Estimated Demand Breakdown by Application
- 10.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
- 10.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
11. Southeast Asia The Neuraminidase Inhibitor Production, Demand (2017-2027)
- 11.1 Current and Estimated Production Breakdown by Type
- 11.2 Current and Estimated Demand Breakdown by Type
- 11.3 Current and Estimated Demand Breakdown by Application
- 11.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
- 11.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
12. Global The Neuraminidase Inhibitor Average Price Trend
- 12.1 Market Price for Each Type of The Neuraminidase Inhibitor in US (2017-2021)
- 12.2 Market Price for Each Type of The Neuraminidase Inhibitor in Europe (2017-2021)
- 12.3 Market Price for Each Type of The Neuraminidase Inhibitor in China (2017-2021)
- 12.4 Market Price for Each Type of The Neuraminidase Inhibitor in Japan (2017-2021)
- 12.5 Market Price for Each Type of The Neuraminidase Inhibitor in India (2017-2021)
- 12.6 Market Price for Each Type of The Neuraminidase Inhibitor in Korea (2017-2021)
- 12.7 Market Price for Each Type of The Neuraminidase Inhibitor in Southeast Asia (2017-2021)
13. Industrial Chain (Impact of COVID-19)
- 13.1 The Neuraminidase Inhibitor Industrial Chain Analysis
- 13.2 Downstream
- 13.3 Impact of COVID-19
- 13.4 Technology Trends of The Neuraminidase Inhibitor
14. The Neuraminidase Inhibitor Competitive Landscape
- 14.1 GlaxoSmithKline
- 14.1.1 GlaxoSmithKline Company Profiles
- 14.1.2 GlaxoSmithKline Product Introduction
- 14.1.3 GlaxoSmithKline The Neuraminidase Inhibitor Sales, Revenue (2017-2021)
- 14.1.4 Strategic initiatives
- 14.2 BioCryst
- 14.2.1 BioCryst Company Profiles
- 14.2.2 BioCryst Product Introduction
- 14.2.3 BioCryst The Neuraminidase Inhibitor Sales, Revenue (2017-2021)
- 14.2.4 Strategic initiatives
- 14.3 Gilead Sciences
- 14.3.1 Gilead Sciences Company Profiles
- 14.3.2 Gilead Sciences Product Introduction
- 14.3.3 Gilead Sciences The Neuraminidase Inhibitor Sales, Revenue (2017-2021)
- 14.3.4 Strategic initiatives
- 14.4 F. Hoffman-La Roche
- 14.4.1 F. Hoffman-La Roche Company Profiles
- 14.4.2 F. Hoffman-La Roche Product Introduction
- 14.4.3 F. Hoffman-La Roche The Neuraminidase Inhibitor Sales, Revenue (2017-2021)
- 14.4.4 Strategic initiatives
- 14.5 Daiichi Sankyo
- 14.5.1 Daiichi Sankyo Company Profiles
- 14.5.2 Daiichi Sankyo Product Introduction
- 14.5.3 Daiichi Sankyo The Neuraminidase Inhibitor Sales, Revenue (2017-2021)
- 14.5.4 Strategic initiatives
15. Conclusion
Summary:
Get latest Market Research Reports on Neuraminidase Inhibitor. Industry analysis & Market Report on Neuraminidase Inhibitor is a syndicated market report, published as (Post-pandemic Era)-Global The Neuraminidase Inhibitor Market Segment Research Report 2021. It is complete Research Study and Industry Analysis of Neuraminidase Inhibitor market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
